UMN Pharma Inc,

Japanese

SHIONOGI

  • About Us
  • Partners
  • Projects
  • News release
  • Contact
  

HOME

  1. Investor Relations
  2. News
Investor Relations
サブ-ナビゲーション
  • 現在位置:News
  • Financial Information
  • Inquiries
  • Disclaimer

News

      

  • 10.30, 2019 withLink Non-consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec.31,2019(Japanese GAAP)

    読む Non-consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec.31,2019(Japanese GAAP)

  • 7.31, 2019 withLink Supplementary Documents of Business Results for First Six Months of Fiscal Year 2019

    読む Supplementary Documents of Business Results for First Six Months of Fiscal Year 2019

  • 7.31, 2019 withLink Non-consolidated Financial Results for the First Six Months of Fiscal Year Ending Dec.31,2019(Japanese GAAP)

    読む Non-consolidated Financial Results for the First Six Months of Fiscal Year Ending Dec.31,2019(Japanese GAAP)

  • 4.26, 2019 withLink Non-consolidated Financial Results for the First Three Months of Fiscal Year Ending Dec.31,2019(Japanese GAAP)

    読む Non-consolidated Financial Results for the First Three Months of Fiscal Year Ending Dec.31,2019(Japanese GAAP)

  • 2.14, 2019 withLink Supplementary Documents of Business Results for Fiscal Year 2018 Ending Dec. 31, 2018

    読む Supplementary Documents of Business Results for Fiscal Year 2018 Ending Dec. 31, 2018

  • 2.14, 2019 withLink Non-consolidated Financial Results for the Fiscal Year Ended Dec.31,2018(Japanese GAAP)

    読む Non-consolidated Financial Results for the Fiscal Year Ended Dec.31,2018(Japanese GAAP)

  • 10.31, 2018 withLink Non-consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec.31,2018(Japanese GAAP)

    読む Non-consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec.31,2018(Japanese GAAP)

  • 7.31, 2018 withLink Supplementary Documents of Business Results for First Six Months of Fiscal Year 2018

    読む Supplementary Documents of Business Results for First Six Months of Fiscal Year 2018

  • 7.31, 2018 withLink Non-consolidated Financial Results for the First Six Months of Fiscal Year Ending Dec.31,2018(Japanese GAAP)

    読む Non-consolidated Financial Results for the First Six Months of Fiscal Year Ending Dec.31,2018(Japanese GAAP)

  • 4.27, 2018 withLink Non-consolidated Financial Results for the First Three Months of Fiscal Year Ending Dec.31,2018(Japanese GAAP)

    読む Non-consolidated Financial Results for the First Three Months of Fiscal Year Ending Dec.31,2018(Japanese GAAP)

  • 2.14, 2018 withLink Supplementary Documents of Business Results for Fiscal Year 2017 Ending Dec. 31, 2017

    読む Supplementary Documents of Business Results for Fiscal Year 2017 Ending Dec. 31, 2017

  • 2.14, 2018 withLink Non-consolidated Financial Results for the Fiscal Year Ended Dec.31,2017(Japanese GAAP)

    読む Non-consolidated Financial Results for the Fiscal Year Ended Dec.31,2017(Japanese GAAP)

  • 10.31, 2017 withLink Notice of signing a capital and business alliance agreement

    読む Notice of signing a capital and business alliance agreement

  • 10.31, 2017 withLink Non-consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec.31,2017(Japanese GAAP)

    読む Non-consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec.31,2017(Japanese GAAP)

  • 7.31, 2017 withLink Supplementary Documents of Business Results for First Six Months of Fiscal Year 2017 Ending Dec. 31, 2017

    読む Supplementary Documents of Business Results for First Six Months of Fiscal Year 2017 Ending Dec. 31, 2017

  • 7.31, 2017 withLink Non-consolidated Financial Results for the First Six Months of Fiscal Year Ending Dec.31,2017(Japanese GAAP)

    読む Non-consolidated Financial Results for the First Six Months of Fiscal Year Ending Dec.31,2017(Japanese GAAP)

  • 4.28, 2017 withLink Non-consolidated Financial Results for the First Three Months of Fiscal Year Ending Dec.31,2017(Japanese GAAP)

    読む Non-consolidated Financial Results for the First Three Months of Fiscal Year Ending Dec.31,2017(Japanese GAAP)

  • 2.22, 2017 withLink Supplementary Documents of Business Results for Fiscal Year 2016 Ended Dec.31, 2016

    読む Supplementary Documents of Business Results for Fiscal Year 2016 Ended Dec.31, 2016

  • 2.20, 2017 withLink Revision of Consolidated Financial Results For the Fiscal Year Ending December 31, 2016

    読む Revision of Consolidated Financial Results For the Fiscal Year Ending December 31, 2016

  • 2.14, 2017 withLink Consolidated Financial Results for the Fiscal Year Ended 31 December 2016 (Japanese GAAP)

    読む Consolidated Financial Results for the Fiscal Year Ended 31 December 2016 (Japanese GAAP)

  • 1.10, 2017 withLink Background of Termination Notice from Astellas of the Agreement to Co-develop ASP7374 (UM-0502) and ASP7373 (UMN-0501) and Alternative Business Plan

    読む Background of Termination Notice from Astellas of the Agreement to Co-develop ASP7374 (UM-0502) and ASP7373 (UMN-0501) and Alternative Business Plan

  • 1.10, 2017 withLink Notice Recieved from Astellas for its Excercise of Termination Right of the Agreement to Co-develop ASP7374 (UM-0502) and ASP7373 (UMN-0501)

    読む Notice Recieved from Astellas for its Excercise of Termination Right of the Agreement to Co-develop ASP7374 (UM-0502) and ASP7373 (UMN-0501)

  • 1.4, 2017 withLink Notice regarding infringement of restrictive covenants of syndicated loans for UNIGEN

    読む Notice regarding infringement of restrictive covenants of syndicated loans for UNIGEN

  • 10.31, 2016 withLink Consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec. 31, 2016 (Japanese GAAP)

    読む Consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec. 31, 2016 (Japanese GAAP)

  • 10.18, 2016 withLink Revision of Consolidated Financial Results Forecasts For the Fiscal Year Ending December 31, 2016

    読む Revision of Consolidated Financial Results Forecasts For the Fiscal Year Ending December 31, 2016

  • 7.29, 2016 withLink Supplementary Documents of Business Results for First Six Months of fiscal Year 2016 ending Dec.31, 2016

    読む Supplementary Documents of Business Results for First Six Months of fiscal Year 2016 ending Dec.31, 2016

  • 7.29, 2016 withLink Consolidated Financial Results for the First Six Months of Fiscal Year Ending December 31, 2016(Japanese GAAP)

    読む Consolidated Financial Results for the First Six Months of Fiscal Year Ending December 31, 2016(Japanese GAAP)

  • 6.29, 2016 withLink UMN Pharma Joins Protein Sciences’ International Zika Vaccine Consortium

    読む UMN Pharma Joins Protein Sciences’ International Zika Vaccine Consortium

  • 5.25, 2016 withLink Supplementary Documents of Consolidated Financial Forecasts for Fiscal Year 2016 ending Dec.31, 2016

    読む Supplementary Documents of Consolidated Financial Forecasts for Fiscal Year 2016 ending Dec.31, 2016

  • 5.25, 2016 withLink Mid-Term Business Plan FY2016-FY2019

    読む Mid-Term Business Plan FY2016-FY2019

  • 4.28, 2016 withLink Consolidated Financial Results for the First Three Months of Fiscal Year Ending December 31, 2016 (Japanese GAAP)

    読む Consolidated Financial Results for the First Three Months of Fiscal Year Ending December 31, 2016 (Japanese GAAP)

  • 2.24, 2016 withLink Supplementary Documents of Business Results for Fiscal Year 2015 Ended Dec.31, 2015

    読む Supplementary Documents of Business Results for Fiscal Year 2015 Ended Dec.31, 2015

  • 2.12, 2016 withLink Consolidated Financial Results for the Fiscal Year Ended 31 December 2015 (Japanese GAAP)

    読む Consolidated Financial Results for the Fiscal Year Ended 31 December 2015 (Japanese GAAP)

  • 2.12, 2016 withLink Protein Sciences and UNIGEN Reach Agreement to Source Flublok® Influenza Vaccine from Japan

    読む Protein Sciences and UNIGEN Reach Agreement to Source Flublok® Influenza Vaccine from Japan

  • 2.12, 2016 withLink Notice regarding the capital investment in UNIGEN Gifu plant

    読む Notice regarding the capital investment in UNIGEN Gifu plant

  • 10.30, 2015 withLink Consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec. 31, 2015 (Japanese GAAP)

    読む Consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec. 31, 2015 (Japanese GAAP)

  • 10.30, 2015 withLink Revision of Consolidated Financial Results Forecasts For the Fiscal Year Ending December 31, 2015

    読む Revision of Consolidated Financial Results Forecasts For the Fiscal Year Ending December 31, 2015

  • 8.24, 2015 titleOnly UMN Pharma relocates Yokohama Headquarters to Shin-Yokohama

  • 8.3, 2015 withLink Revised Supplement Documents for Financial Results for First half of FY 2015 Ending Dec.31, 2015

    読む Revised Supplement Documents for Financial Results for First half of FY 2015 Ending Dec.31, 2015

  • 7.31, 2015 withLink Supplement Documents for Financial Results for First half of FY 2015 Ending Dec.31, 2015

    読む Supplement Documents for Financial Results for First half of FY 2015 Ending Dec.31, 2015

  • 7.31, 2015 withLink Consolidated Financial Results for the First Six Months of Fiscal Year Ending Dec. 31, 2015 (Japanese GAAP)

    読む Consolidated Financial Results for the First Six Months of Fiscal Year Ending Dec. 31, 2015 (Japanese GAAP)

  • 4.30, 2015 withLink Consolidated Financial Results for the First Quarter of Fiscal Year Ending Dec. 31, 2015 (Japanese GAAP)

    読む Consolidated Financial Results for the First Quarter of Fiscal Year Ending Dec. 31, 2015 (Japanese GAAP)

  • 2.13, 2015 withLink Supplement Documents for Financial Results for Fiscal Year 2014 Ended Dec. 31, 2014

    読む Supplement Documents for Financial Results for Fiscal Year 2014 Ended Dec. 31, 2014

  • 2.13, 2015 withLink Consolidated Financial Results for the Fiscal Year Ended 31 December 2014 (Japanese GAAP)

    読む Consolidated Financial Results for the Fiscal Year Ended 31 December 2014 (Japanese GAAP)

  • 12.22, 2014 withLink Protein Sciences, UMN Pharma and IHI Corporation Enter into an Agreement to Evaluate Sourcing Flublok® from Japan

    読む Protein Sciences, UMN Pharma and IHI Corporation Enter into an Agreement to Evaluate Sourcing Flublok® from Japan

  • 7.31, 2014 withLink UMN Pharma Announces Financial Results for First half of FY2014

    読む UMN Pharma Announces Financial Results for First half of FY2014

  • 5.30, 2014 withLink Astellas and UMN Announce Submission of Application for Marketing Approval of Recombinant Influenza HA Vaccine ASP7374 in Japan

    読む Astellas and UMN Announce Submission of Application for Marketing Approval of Recombinant Influenza HA Vaccine ASP7374 in Japan

  • 2.17, 2014 withLink UMN Pharma Announces Financial Results for Fiscal Year 2013

    読む UMN Pharma Announces Financial Results for Fiscal Year 2013

  • 2.14, 2014 withLink Daiichi Sankyo and UMN Pharma Enter into Collaborative Research Agreement for Norovirus Vaccine

    読む Daiichi Sankyo and UMN Pharma Enter into Collaborative Research Agreement for Norovirus Vaccine

  • 1.15, 2014 withLink Astellas and UMN Announce Summary Results in Phase III Clinical Trials of Seasonal Flu Vaccine UMN-0502(ASP7374)

    読む Astellas and UMN Announce Summary Results in Phase III Clinical Trials of Seasonal Flu Vaccine UMN-0502(ASP7374)

  • 10.21, 2013 withLink Astellas and UMN announce Completion of Administration of Phase III Clinical Trials of Seasonal Flu Vaccine UMN-0502(ASP7374)

    読む Astellas and UMN announce Completion of Administration of Phase III Clinical Trials of Seasonal Flu Vaccine UMN-0502(ASP7374)

  • 6.11, 2013 withLink Dr. Masahiro Michishita, Chairman & CEO of UMN Pharma, will give a presentation at Cell Culture Engineering World Asia

    読む Dr. Masahiro Michishita, Chairman & CEO of UMN Pharma, will give a presentation at Cell Culture Engineering World Asia

  • 4.1, 2013 withLink UNIGEN, a UMN Pharma subsidairy started a trial operation in Gifu Plant

    読む UNIGEN, a UMN Pharma subsidairy started a trial operation in Gifu Plant

  • 4.1, 2013 withLink UMN Pharma relocates Yokohama Headquarters to Minato Mirai

    読む UMN Pharma relocates Yokohama Headquarters to Minato Mirai

  • 3.28, 2013 withLink UMN Pharma Announces Change in Representative Director (CEO)

    読む UMN Pharma Announces Change in Representative Director (CEO)

  • 3.11, 2013 withLink Non-inferiority Observed in Phase III Clinical Trials of Seasonal Flu Vaccine UMN-0502(ASP7374)

    読む Non-inferiority Observed in Phase III Clinical Trials of Seasonal Flu Vaccine UMN-0502(ASP7374)

  • 3.6, 2013 withLink UMN Pharma, API, and Yakult Honsha Sign Letter of Intent to Co-develop and Commercialize Biosimilars

    読む UMN Pharma, API, and Yakult Honsha Sign Letter of Intent to Co-develop and Commercialize Biosimilars

  • 1.17, 2013 withLink U.S. FDA Approves Flublok®, the World’s First Recombinant, Highly Purified, Egg-Free Influenza Vaccine pdf (546KB)

  • 12.18, 2012 withLink UMN Pharma Announces Collaboration with ILDONG Pharmaceutical for Recombinant Influenza HA Vaccines in South Korea

    読む UMN Pharma Announces Collaboration with ILDONG Pharmaceutical for Recombinant Influenza HA Vaccines in South Korea

  • 12.12, 2012 withLink Catalent and UMN Pharma announce collaboration for biosimilar development and production in Japan

    読む Catalent and UMN Pharma announce collaboration for biosimilar development and production in Japan

  • 12.11, 2012 withLink Administration of Seasonal Flu Vaccine UMN-0502 (ASP7374) Completed in Phase III Clinical Trial

    読む Administration of Seasonal Flu Vaccine UMN-0502 (ASP7374) Completed in Phase III Clinical Trial

  • 12.11, 2012 withLink UMN Pharma Stock Listed on Mothers

    読む UMN Pharma Stock Listed on Mothers

  • 11.6, 2012 withLink UMN Pharma Receives Approval to List on Tokyo Stock Exchange Mothers

    読む UMN Pharma Receives Approval to List on Tokyo Stock Exchange Mothers

  • 10.9, 2012 withLink Memorandum of Understandings for the Co-development and Exclusive Commercialization Rights of UMN Pharma’s Recombinant Influenza HA Vaccine in South Korea with ILDONG PHARMACEUTICAL

    読む Memorandum of Understandings for the Co-development and Exclusive Commercialization Rights of UMN Pharma’s Recombinant Influenza HA Vaccine in South Korea with ILDONG PHARMACEUTICAL

  • 9.13, 2012 withLink UNIGEN, a UMN Pharma Subsidiary, Designated as Gifu Prefectural Government's “Subsidy for Promotion of Establishment of New Business Facilities”

    読む UNIGEN, a UMN Pharma Subsidiary, Designated as Gifu Prefectural Government's “Subsidy for Promotion of Establishment of New Business Facilities”

  • 3.29, 2012 withLink Tatsuyoshi Hirano Takes Office as New CEO

    読む Tatsuyoshi Hirano Takes Office as New CEO

  • 3.13, 2012 withLink Immunogenicity and Favorable Tolerability Observed in Phase II Clinical Trial for H5N1 Influenza Vaccine UMN-0501 (ASP7373)

    読む Immunogenicity and Favorable Tolerability Observed in Phase II Clinical Trial for H5N1 Influenza Vaccine UMN-0501 (ASP7373)

  • 3.6, 2012 withLink UNIGEN Commences Construction of World-Class Biopharmaceutical Manufacturing Plant

    読む UNIGEN Commences Construction of World-Class Biopharmaceutical Manufacturing Plant

  • 2.22, 2012 withLink Protein Sciences Licenses Proprietary expresSF+® Insect Cell Technology to Merck

    読む Protein Sciences Licenses Proprietary expresSF+® Insect Cell Technology to Merck

  • 2.14, 2012 withLink UMN Pharma entered into a licensing agreement with Timo Vesikari, M.D. and Vesna Blazevic, Ph.D. that provides UMN Pharma with exclusive worldwide rights to develop and commercialize a novel norovirus VLP + rotavirus VP6 non-live injectable vaccine.

    読む UMN Pharma entered into a licensing agreement with Timo Vesikari, M.D. and Vesna Blazevic, Ph.D. that provides UMN Pharma with exclusive worldwide rights to develop and commercialize a novel norovirus VLP + rotavirus VP6 non-live injectable vaccine.

  • 2.7, 2012 withLink UNIGEN, a UMN Pharma Subsidiary, Selected in First Round of METI's FY 2011 “Subsidy for Domestic Location Promotion Projects”

    読む UNIGEN, a UMN Pharma Subsidiary, Selected in First Round of METI's FY 2011 “Subsidy for Domestic Location Promotion Projects”

  • 12.21, 2011 withLink Favorable Immunogenicity and Tolerability Observed in Phase I/II Clinical Trial for Seasonal Flu Vaccine UMN-0502 (ASP7374)

    読む Favorable Immunogenicity and Tolerability Observed in Phase I/II Clinical Trial for Seasonal Flu Vaccine UMN-0502 (ASP7374)

  • 11.11, 2011 withLink Administration of H5N1 Influenza Vaccine UMN-0501 (ASP7373) Completed in Phase II Clinical Trial

    読む Administration of H5N1 Influenza Vaccine UMN-0501 (ASP7373) Completed in Phase II Clinical Trial

  • 9.15, 2011 withLink Administration of Seasonal Flu Vaccine UMN-0502 (ASP7374) Completed in Phase I/II Clinical Trial

    読む Administration of Seasonal Flu Vaccine UMN-0502 (ASP7374) Completed in Phase I/II Clinical Trial

  • 7.1, 2011 withLink UMN Pharma CEO, Shu-ichi Kanazashi, Makes Special-Session Presentation at 10th Int'l Bio Expo Japan, 2011

    読む UMN Pharma CEO, Shu-ichi Kanazashi, Makes Special-Session Presentation at 10th Int'l Bio Expo Japan, 2011

  • 4.1, 2011 withLink Akita Plant Commenced Operations: A new manufacturing technology development center

    読む Akita Plant Commenced Operations: A new manufacturing technology development center

  • 11.9, 2010 withLink UMN Pharma secures exclusive rights from Protein Sciences Corporation to commercialize influenza vaccines in China, Hong Kong, Korea, Singapore and Taiwan

    読む UMN Pharma secures exclusive rights from Protein Sciences Corporation to commercialize influenza vaccines in China, Hong Kong, Korea, Singapore and Taiwan

  • 11.4, 2010 withLink Protein Sciences Corporation and Emergent BioSolutions, Inc. reach agreement to end all litigation and entanglements between the companies

    読む Protein Sciences Corporation and Emergent BioSolutions, Inc. reach agreement to end all litigation and entanglements between the companies

  • 9.30, 2010 withLink Astellas and UMN Pharma enter into the definitive agreement for UMN Pharma’s Cell Culture Based Influenza Vaccine Programs in Japan

    読む Astellas and UMN Pharma enter into the definitive agreement for UMN Pharma’s Cell Culture Based Influenza Vaccine Programs in Japan

  • 8.17, 2010 withLink Astellas Pharma Inc. and UMN Pharma Inc. Entered into a Memorandum of Understandings for UMN Pharma's Cell Culture Based Influenza Vaccine Program in Japan

    読む Astellas Pharma Inc. and UMN Pharma Inc. Entered into a Memorandum of Understandings for UMN Pharma's Cell Culture Based Influenza Vaccine Program in Japan

  • 4.20, 2010 withLink UMN Pharma Confirms Immunogenicity and Safety of Avian Influenza A (H5N1) Vaccine Manufactured from Cell-Culture, UMN-0501 in Phase II Clinical Trial

    読む UMN Pharma Confirms Immunogenicity and Safety of Avian Influenza A (H5N1) Vaccine Manufactured from Cell-Culture, UMN-0501 in Phase II Clinical Trial

  • 4.16, 2010 withLink API and UMN Pharma Announce Formulation Process Collaboration

    読む API and UMN Pharma Announce Formulation Process Collaboration

  • 1.26, 2010 withLink IHI Corporation and UMN Pharma Announce Manufacturing Collaboration

    読む IHI Corporation and UMN Pharma Announce Manufacturing Collaboration

  • 10.5, 2009 withLink UMN Pharma initiates phase II clinical trial for avian influenza A (H5N1) vaccine manufactured from cell-culture, UMN-0501.

    読む UMN Pharma initiates phase II clinical trial for avian influenza A (H5N1) vaccine manufactured from cell-culture, UMN-0501.

  • 6.29, 2009 withLink Protein Sciences Corporation signs a contract which amounts to about 147 million dollars with U.S. Department of Health and Human Services for new way to make flu vaccine.

    読む Protein Sciences Corporation signs a contract which amounts to about 147 million dollars with U.S. Department of Health and Human Services for new way to make flu vaccine.

  • 2.16, 2009 withLink UMN Pharma Secures additional investment from IPEC.

    読む UMN Pharma Secures additional investment from IPEC.

  • 2.13, 2009 withLink UMN Pharma presents favorable results from Phase I/II study of UMN-0501 at World Health Organization (WHO) pandemic influenza meeting.

    読む UMN Pharma presents favorable results from Phase I/II study of UMN-0501 at World Health Organization (WHO) pandemic influenza meeting.

  • 1.15, 2009 withLink UMN Pharma Confirms Immunogenicity and Safety of UMN-0501 Pandemic Influenza Vaccine in Phase I/II Clinical Trials.

    読む UMN Pharma Confirms Immunogenicity and Safety of UMN-0501 Pandemic Influenza Vaccine in Phase I/II Clinical Trials.

  • 12.22, 2008 titleOnly Relocation of Tokyo Head Office to Yokohama. Renamed as Yokohama Head Office.

  • 8.22, 2008 withLink UMN Pharma begins preparations for construction of a manufacturing facility for UMN-0501, a pandemic influenza vaccine manufactured using a novel cell culture technique.

    読む UMN Pharma begins preparations for construction of a manufacturing facility for UMN-0501, a pandemic influenza vaccine manufactured using a novel cell culture technique.

  • 6.18, 2008 withLink UMN Pharma initiates phase I/II trials for pandemic influenza vaccine manufactured from cell-culture, UMN-0501.

    読む UMN Pharma initiates phase I/II trials for pandemic influenza vaccine manufactured from cell-culture, UMN-0501.

  • 6.10, 2008 withLink UMN pandemic influenza vaccine, UMN-0501 designated as orphan drug.

    読む UMN pandemic influenza vaccine, UMN-0501 designated as orphan drug.

  • 4.30, 2008 withLink UMN Pharma acquires factory site in Akita for the manufacturing of pandemic influenza vaccine.

    読む UMN Pharma acquires factory site in Akita for the manufacturing of pandemic influenza vaccine.

  • 4.10, 2008 withLink UMN Pharma announced initiation of phase I/II clinical trials for UMN-0501, UMN's pandemic influenza vaccine.

    読む UMN Pharma announced initiation of phase I/II clinical trials for UMN-0501, UMN's pandemic influenza vaccine.

  • 4.11, 2007 withLink The result of a clinical study of FluBlØk (UMN-05) in the US is published in JAMA (The Journal of The American Medical Association).

    読む The result of a clinical study of FluBlØk (UMN-05) in the US is published in JAMA (The Journal of The American Medical Association).

  • 2.21, 2007 withLink UMN Pharma completes $18.9 million Series C financing round, with participation of 20 investors.

    読む UMN Pharma completes $18.9 million Series C financing round, with participation of 20 investors.

  • 8.29, 2006 withLink UMN Pharma signs a license agreement of UMN-05 with Protein Sciences Corporation.

    読む UMN Pharma signs a license agreement of UMN-05 with Protein Sciences Corporation.

  • 2.3, 2006 withLink UMN Pharma completes $7.5 million Series B-2 financing round, with participation of 11 investors.

    読む UMN Pharma completes $7.5 million Series B-2 financing round, with participation of 11 investors.

  • 10.17, 2005 withLink UMN Pharma completes $1.1 million Series B-1 financing round, with participation of 3 venture capital firms.

    読む UMN Pharma completes $1.1 million Series B-1 financing round, with participation of 3 venture capital firms.

  • 7.22, 2005 withLink UMN Pharma completes $0.9 million Series A round (second tranche), with participation of 2 venture capital firms.

    読む UMN Pharma completes $0.9 million Series A round (second tranche), with participation of 2 venture capital firms.

  • 12.31, 2004 withLink UMN Pharma completes $0.9 million Series A round (first tranche), with participation of 2 venture capital firms.

    読む UMN Pharma completes $0.9 million Series A round (first tranche), with participation of 2 venture capital firms.